Functional association of the N‐terminal residues with the central region in glucagon‐related peptides

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Peptide Science

• Publication date

  2011-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/psc.1385PMID 21661079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Charge inversion at position 68 of the glucagon and glucagon‐like peptide‐1 receptors supports selectivity in hormone action

  2011cited by this paper
• A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1.

  2011cited by this paper
• Understanding GLP-1 Analogs and Enhancing Patient Success

  2010cited by this paper
• Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges.

  2010cited by this paper
• In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences.

  2009cited by this paper
• Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists

  2009cited by this paper
• Passing the baton in class B GPCRs: peptide hormone activation via helix induction?

  2009cited by this paper
• A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

  2009cited by this paper
• Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor*

  2009cited by this paper
• Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.

  2008cited by this paper
• Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain*

  2008cited by this paper
• In Situ Neutralization in Boc-chemistry Solid Phase Peptide Synthesis

  2007cited by this paper
• Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.

  2007cited by this paper
• The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation.

  2006cited by this paper
• The biology of incretin hormones.

  2006cited by this paper
• Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor Antagonist*

  2006cited by this paper
• Using evolutionary information and ancestral sequences to understand the sequence-function relationship in GLP-1 agonists.

  2006cited by this paper
• Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes

  2005cited by this paper
• Incretins, insulin secretion and Type 2 diabetes mellitus

  2004cited by this paper
• The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.

  2004cited by this paper
• Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production.

  2004cited by this paper
• A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptors

  2003cited by this paper
• Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity

  2003cited by this paper
• The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.

  2003cited by this paper
• Three Distinct Epitopes on the Extracellular Face of the Glucagon Receptor Determine Specificity for the Glucagon Amino Terminus*

  2003cited by this paper
• The glucagon‐like peptide‐1 receptor binding site for the N‐terminus of GLP‐1 requires polarity at Asp198 rather than negative charge

  2002cited by this paper
• Residue 19 of the parathyroid hormone (PTH) modulates ligand interaction with the juxtamembrane region of the PTH-1 receptor.

  2002cited by this paper
• Molecular determinants of glucagon receptor signaling.

  2002cited by this paper
• Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1.

  2002cited by this paper
• Peptide conformational changes induced by tryptophan-phosphocholine interactions in a micelle.

  2002cited by this paper
• NMR studies of the aggregation of glucagon‐like peptide‐1: formation of a symmetric helical dimer

  2002cited by this paper
• Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states.

  2001cited by this paper
• Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.

  2001cited by this paper
• Biological activity of GLP-1-analogues with N-terminal modifications.

  1999cited by this paper
• In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera.

  1999cited by this paper
• Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

  1999cited by this paper
• Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

  1999cited by this paper
• Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

  1999cited by this paper
• Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

  1998cited by this paper
• The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action.

  1997cited by this paper
• Transmembrane Residues of the Parathyroid Hormone (PTH)/PTH-related Peptide Receptor That Specifically Affect Binding and Signaling by Agonist Ligands*

  1996cited by this paper
• Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

  1995cited by this paper
• Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR.

  1994cited by this paper
• Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes.

  1994cited by this paper
• Structure/activity characterization of glucagon-like peptide-1.

  1994cited by this paper
• Structure-activity studies of glucagon-like peptide-1.

  1994cited by this paper
• Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

  1993cited by this paper
• Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

  1993cited by this paper
• Comparison of half-disappearance times, distribution volumes and metabolic clearance rates of exogenous glucagon-like peptide 1 and glucagon in rats.

  1988cited by this paper

• Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity.

  2023cites this paper
• Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

  2022cites this paper
• Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.

  2022cites this paper
• Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

  2021cites this paper
• Drug discovery approaches targeting the incretin pathway.

  2020cites this paper
• A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.

  2020cites this paper
• Multifunctional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide Receptors.

  2016cites this paper
• Design of Potent and Proteolytically Stable Oxyntomodulin Analogs.

  2016cites this paper
• A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction.

  2013cites this paper
• The activation of the glucagon-like peptide-1 (GLP-1) receptor by peptide and non-peptide ligands

  2013cites this paper
• Peptide lipidation stabilizes structure to enhance biological function.

  2013cites this paper
• A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.

  2013cites this paper
• The structure and function of the glucagon‐like peptide‐1 receptor and its ligands

  2012influential citation
• Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents

  2012cites this paper
• PVN pathways controlling energy homeostasis

  2012cites this paper
• Targeting the glucagon receptor family for diabetes and obesity therapy.

  2012cites this paper